Please assess the completion status of the following clinical trial:

Trial Title: Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~MS as defined by the modified McDonald s criteria (Polman, Reingold et al. 2005)~SP-MS as documented by lack of MS relapse for the past 1 year and non-remitting/sustained (\> 3 months) progression of disability~Age 18-65, inclusive, at the time of the first screening baseline visit~EDSS 3.0 to 7.0, inclusive, at the time of the first screening baseline visit~Able to provide informed consent~Willing to participate in all aspects of trial design and follow-up~Lack of CEL on all MRIs performed within the last 12 months or if patient has CEL, then documentation that they tried and failed or could not tolerate FDA approved disease modifying therapies (DMTh)~Not receiving any DMTh (such as IFN-beta preparation, glatiramer acetate, corticosteroid, natalizumab, fingolimod, immunosuppressive agents or experimental therapeutics) for a period of at least 1 month before enrollment in the study, allowing for at least a 1-year~period off therapy prior to the first study dose~Agreeing to commit to the use of a reliable/accepted method of birth control (i.e. hormonal contraception (birth control pills, injected hormones, vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom with spermicide) or they have undergone surgical sterilization (such as hysterectomy, tubal ligation, or vasectomy)) during enrollment in the study and through 12 months after the last dose of study drug~EXCLUSION CRITERIA:~RR-MS or PP-MS~Evidence of clearly documented MS relapse within the last 1 year~Alternative diagnoses that can explain neurological disability and MRI findings~Clinically significant medical disorders that, in the judgment of the investigators could cause CNS tissue damage, limit its repair, expose the patient to undue risk of harm or prevent the patient from completing the study (such as, but not limited to cerebrovascular disease, ischemic cardiomyopathy, clotting disorder, brittle diabetes, neurodegenerative disorder)~Pregnant or breastfeeding female~History or sign of congenital or acquired immunodeficiency or chronic infections, such as HIV/AIDS, Hepatitis A, B or C, HTLV-1 carrier and others that would expose patient to risks of pathogen reactivation associated with rituximab treatment~Abnormal screening/baseline blood tests exceeding any of the limits defined below:~1. Serum alanine transaminase or aspartate transaminase levels which are greater than three times the upper limit of normal values.~2. Total white blood cell count \< 3 000/mm(3)~3. Platelet count \< 85 000/mm(3)~4. Serum creatinine level \> 2.0 mg/dl and eGFR (glomerular filtration rate) \< 60~5. Serological evidence of HIV, HTLV-1 or active hepatitis A, B or C~6. Positive pregnancy test~7. Positive CSF or serum quantitative PCR for JC virus on CSF collected from the baseline spinal tap (test will be performed by CLIA certified laboratory of Gene Major, NINDS)~8. Total serum IgG \< 600mg/dl (nl 642-1730mg/dl) or total serum IgM \< 30mg/dl (nl 34-342mg/dl) as these Ig deficiencies would suggest underlying abnormalities with B cell function/maturation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
- Baseline (Type: NO_INTERVENTION): Patients in their first year baseline prior to study drug phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy